Pancreatic Cancer Research

ResearcherUniversity of PisaActive in the last 2 years

Maarten F. Bijlsma

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6627-3229; OpenAlex author ID A5000969662, A5086619378. Sources: OpenAlex.

Their work

Papers
71 (first author 5, last author 16)
Trials
0
Grants
0
Labs led
2
Collaborators
149
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 5 papers · 2016: 2 papers · 2017: 2 papers · 2018: 5 papers · 2019: 4 papers · 2020: 11 papers · 2021: 9 papers · 2022: 6 papers · 2023: 6 papers · 2024: 7 papers · 2025: 9 papers · 2026: 4 papers

Papers 50 of 71

  1. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  2. Precision targeting of stromal states in pancreatic cancer: a clinical perspective. First author DOI 10.1016/j.trecan.2026.07.003↗
  3. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  4. Estrogen Production in Pancreatic Cancer Shapes a Tumor-Suppressive Stromal Microenvironment. Last author DOI 10.1158/0008-5472.can-24-4707↗
  5. Association of epigenetic landscapes with heterogeneity and plasticity in pancreatic cancer. Last author DOI 10.1016/j.critrevonc.2024.104573↗
  6. KRAS mutation status integrated with RNA subtyping improves prognostic modeling in FOLFIRINOX-treated metastatic pancreatic cancer. Last author DOI 10.1016/j.medj.2025.100601↗
  7. Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models. Last author DOI 10.1016/j.semcancer.2024.12.003↗
  8. CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research. Co-author DOI 10.1016/j.semcancer.2025.07.004↗
  9. Tumor gene expression is associated with venous thromboembolism in patients with ductal pancreatic adenocarcinoma. Co-author DOI 10.1016/j.thromres.2024.109240↗
  10. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  11. A pleiotropy scan to discover new susceptibility loci for pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/mutage/geae012↗
  12. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  13. Stromal Hedgehog Signaling Is Associated with Favorable Outcomes in Pancreatic Cancer. Last author DOI 10.3390/ijms26115200↗
  14. Kinase activities in pancreatic ductal adenocarcinoma with prognostic and therapeutic avenues. Last author DOI 10.1002/1878-0261.13625↗
  15. CAPN2-responsive mesoporous silica nanoparticles: A promising nanocarrier for targeted therapy of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2024.216845↗
  16. Transcriptome-based classification to predict FOLFIRINOX response in a real-world metastatic pancreatic cancer cohort. Last author DOI 10.1016/j.trsl.2024.08.002↗
  17. Identification of pancreatic cancer-specific protease substrates for protease-dependent targeted delivery. Co-author DOI 10.1038/s41389-024-00542-1↗
  18. Pancreatic cancer-associated fibroblasts modulate macrophage differentiation via sialic acid-Siglec interactions. Co-author DOI 10.1038/s42003-024-06087-8↗
  19. Polymorphisms in transcription factor binding sites and enhancer regions and pancreatic ductal adenocarcinoma risk. Co-author DOI 10.1186/s40246-024-00576-x↗
  20. Hypoxia Abrogates Tumor-Suppressive Activities of C/EBPδ in Pancreatic Cancer. Co-author DOI 10.3390/ijms25179449↗
  21. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. Last author DOI 10.1002/ijc.34276↗
  22. Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.celrep.2023.112581↗
  23. The PANcreatic Disease ReseArch (PANDoRA) consortium: Ten years' experience of association studies to understand the genetic architecture of pancreatic cancer. Co-author DOI 10.1016/j.critrevonc.2023.104020↗
  24. Genetic and non-genetic risk factors for early-onset pancreatic cancer. Co-author DOI 10.1016/j.dld.2023.02.023↗
  25. C/EBP-Family Redundancy Determines Patient Survival and Lymph Node Involvement in PDAC. Co-author DOI 10.3390/ijms24021537↗
  26. Preclinical Assessment of ADAM9-Responsive Mesoporous Silica Nanoparticles for the Treatment of Pancreatic Cancer. Co-author DOI 10.3390/ijms241310704↗
  27. Analysis of the glyco-code in pancreatic ductal adenocarcinoma identifies glycan-mediated immune regulatory circuits. Co-author DOI 10.1038/s42003-021-02934-0↗
  28. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study. Co-author DOI 10.1093/bjs/znac272↗
  29. The contributions of hypoxia to poor outcomes in pancreatic cancer. Co-author DOI 10.21037/tcr-22-2167↗
  30. Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fcell.2022.875836↗
  31. C/EBPδ Suppresses Motility-Associated Gene Signatures and Reduces PDAC Cell Migration. Co-author DOI 10.3390/cells11213334↗
  32. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview. Co-author DOI 10.3390/pharmaceutics14020390↗
  33. Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer. Co-author DOI 10.1016/j.celrep.2021.109852↗
  34. The case for a stratified application of targeted agents against pancreatic cancer. Co-author DOI 10.1016/j.ebiom.2021.103344↗
  35. Readily available biomarkers predict poor survival in metastatic pancreatic cancer. Co-author DOI 10.1080/1354750x.2021.1893814↗
  36. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  37. Genetic Polymorphisms Involved in Mitochondrial Metabolism and Pancreatic Cancer Risk. Co-author DOI 10.1158/1055-9965.epi-21-0353↗
  38. Focal adhesion kinase inhibition synergizes with nab-paclitaxel to target pancreatic ductal adenocarcinoma. First author DOI 10.1186/s13046-021-01892-z↗
  39. The Cellular Origins of Cancer-Associated Fibroblasts and Their Opposing Contributions to Pancreatic Cancer Growth. First author DOI 10.3389/fcell.2021.743907↗
  40. Non-Tumor CCAAT/Enhancer-Binding Protein Delta Potentiates Tumor Cell Extravasation and Pancreatic Cancer Metastasis Formation. Co-author DOI 10.3390/biom11081079↗
  41. ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer. Co-author DOI 10.3390/cancers13133321↗
  42. Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32586↗
  43. Co-expression analysis of pancreatic cancer proteome reveals biology and prognostic biomarkers. Co-author DOI 10.1007/s13402-020-00548-y↗
  44. Macrophage-secreted MMP9 induces mesenchymal transition in pancreatic cancer cells via PAR1 activation. Co-author DOI 10.1007/s13402-020-00549-x↗
  45. Unsupervised class discovery in pancreatic ductal adenocarcinoma reveals cell-intrinsic mesenchymal features and high concordance between existing classificati… Last author DOI 10.1038/s41598-019-56826-9↗
  46. Microdissected pancreatic cancer proteomes reveal tumor heterogeneity and therapeutic targets. Last author DOI 10.1172/jci.insight.138290↗
  47. Early macrophage infiltrates impair pancreatic cancer cell growth by TNF-α secretion. Co-author DOI 10.1186/s12885-020-07697-1↗
  48. High-grade mesenchymal pancreatic ductal adenocarcinoma drives stromal deactivation through CSF-1. Last author DOI 10.15252/embr.201948780↗
  49. Combined Expression of Plasma Thrombospondin-2 and CA19-9 for Diagnosis of Pancreatic Cancer and Distal Cholangiocarcinoma: A Proteome Approach. Co-author DOI 10.1634/theoncologist.2019-0680↗
  50. Matrix Metalloproteases in Pancreatic Ductal Adenocarcinoma: Key Drivers of Disease Progression? Co-author DOI 10.3390/biology9040080↗

Closest collaborators

The 25 strongest of 149 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanneke W.M. van Laarhoven · 31 shared papers, 2015–2026 · strength 4.24
  2. C. Arnold Spek · 14 shared papers, 2018–2024 · strength 2.53
  3. Marc G. Besselink · 16 shared papers, 2015–2026 · strength 1.96
  4. Johanna W. Wilmink · 13 shared papers, 2015–2026 · strength 1.92
  5. Paul Manoukian · 8 shared papers, 2021–2026 · strength 1.86
  6. Frederike Dijk · 13 shared papers, 2018–2026 · strength 1.76
  7. Geert Kazemier M · 11 shared papers, 2016–2026 · strength 1.39
  8. Joanne Verheij · 10 shared papers, 2020–2026 · strength 1.38
  9. Etienne J. Slapak · 6 shared papers, 2020–2024 · strength 1.27
  10. Elisa Giovannetti · 11 shared papers, 2016–2024 · strength 1.26
  11. Marjolein F. Lansbergen · 5 shared papers, 2024–2026 · strength 1.07
  12. Mark P.G. Dings · 7 shared papers, 2020–2026 · strength 1.07
  13. JanWillem Duitman · 6 shared papers, 2020–2024 · strength 1.02
  14. Izaak Quintus Molenaar · 6 shared papers, 2022–2026 · strength 0.99
  15. Connie R. Jiménez · 8 shared papers, 2017–2024 · strength 0.92
  16. Ignace H. J. T. de Hingh · 5 shared papers, 2023–2026 · strength 0.91
  17. Judith de Vos‐Geelen · 5 shared papers, 2021–2026 · strength 0.88
  18. Marjolein Y.V. Homs · 5 shared papers, 2021–2026 · strength 0.88
  19. Leonie Hartl · 5 shared papers, 2020–2024 · strength 0.88
  20. Casper H.J. van Eijck · 5 shared papers, 2019–2026 · strength 0.82
  21. Bert A. Bonsing · 5 shared papers, 2022–2025 · strength 0.81
  22. Tessa Y. S. Le Large · 8 shared papers, 2016–2022 · strength 0.75
  23. Helene Damhofer · 6 shared papers, 2013–2025 · strength 0.64
  24. Jeanin Elise van Hooft · 5 shared papers, 2018–2026 · strength 0.61
  25. Cansu Tekin · 5 shared papers, 2018–2020 · strength 0.61

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.